Bay Area Institute Aims to Fast-Track Cardio-Renal Disease Cures

CONCORD, CA – April 02, 2026 – A new, state-of-the-art research facility launched today in Concord, promising to accelerate the development of therapies for a complex and deadly web of interconnected health conditions affecting tens of millions of Americans. Panoramic Science, the research arm of Panoramic Health, has partnered with the West Coast Kidney Institute to open the Concord Cardio-Renal Research Institute, a center designed specifically to tackle the challenges of cardio-renal-metabolic (CRM) diseases.

The launch represents a significant strategic investment in a critical area of unmet medical need, creating a dedicated hub in the Bay Area to fast-track clinical trials and connect patients with potentially life-saving investigational treatments.

A Targeted Attack on a Complex Disease Nexus

The institute's focus on cardio-renal-metabolic diseases addresses one of the most pressing public health crises of the 21st century. This cluster of conditions, which includes cardiovascular disease, chronic kidney disease (CKD), and type 2 diabetes, is not just a collection of separate ailments but a deeply intertwined syndrome. Each condition exacerbates the others, creating a vicious cycle that leads to poor patient outcomes and staggering healthcare costs.

Recent data paints a stark picture of the problem's scale. In the United States alone, more than one in four adults—approximately 70 million people—suffers from at least one of these CRM conditions. The problem is escalating, with the prevalence of patients having two or more of these diseases rising significantly in the last two decades. The burden is particularly heavy on older adults, but alarmingly, a significant percentage of adolescents are already showing early signs of risk.

The economic impact is just as profound. The direct healthcare cost of cardiorenal disease in the U.S. is projected to reach an astronomical $4.8 trillion between 2021 and 2030. This cost is driven by hospitalizations and the management of severe complications, as many patients, particularly those with chronic kidney disease, are diagnosed late when their options are limited and more expensive. This reactive approach to care has created a major gap between available knowledge and real-world practice.

Despite the development of promising new drug classes, a significant "treatment gap" persists. Guideline-recommended therapies that offer proven cardiorenal protection are underutilized, and care remains fragmented, with patients often seeing separate specialists for their heart, kidney, and metabolic issues without a coordinated strategy. The Concord Cardio-Renal Research Institute is designed to directly confront this fragmented landscape.

The 'Integrated' Advantage: Fusing Care and Discovery

The core innovation of the Concord institute lies in its unique "integrated model." By co-locating the 2,000-square-foot dedicated research facility within a multidisciplinary medical office, the center breaks down the traditional walls between clinical care and clinical research. This fusion is expected to overcome systemic bottlenecks that have long plagued drug development.

"We're focused on connecting complex patients with the latest investigational therapies while helping address systemic enrollment challenges that slow drug development," said Lisa Kiehne, President of Panoramic Science, in a statement. "We are excited to establish the Concord site as a center of excellence that brings together clinical expertise, infrastructure, and access to better serve patients and support our sponsor partners."

The facility is purpose-built to handle complex study protocols. It features three research exam rooms, advanced infusion capabilities, and specialized equipment for pharmacokinetic sampling—a key process in understanding how a drug moves through the body. With secure investigational drug storage and the capacity for extended observation visits, the site is equipped to conduct complex, early-stage trials that are often difficult to implement in standard clinical settings.

This integrated approach provides immediate access to a large, diverse patient population already being treated for CRM conditions, dramatically streamlining the often-arduous process of trial recruitment. For patients, it offers the convenience of receiving both their regular care and trial-related services in a familiar setting, which can improve retention and reduce the burden of participation. More importantly, the on-site presence of nephrology, cardiology, and supportive services like nutritional counseling ensures comprehensive oversight and enhances patient safety throughout a trial.

Strengthening the Bay Area's Life Science Ecosystem

The Concord facility is the third research site for Panoramic Science in the Bay Area and a key part of its growing national network of more than 20 sites. This expansion solidifies the region's reputation as a global epicenter for life science innovation, adding a specialized capability for one of medicine's most challenging fields.

The institute will be led by a team of highly experienced investigators. Dr. Edward Kim and Dr. Rohit Sharma, both board-certified nephrologists with extensive research backgrounds, will spearhead the site's primary activities. They are joined by Dr. Michael Murphy, who will oversee trials related to medical devices and access procedures, adding another layer of specialized expertise.

This leadership brings deep clinical and research acumen, providing the credibility and know-how needed to attract cutting-edge trials from pharmaceutical and biotech sponsors. For these sponsors, the institute offers a reliable and efficient partner capable of delivering high-quality data.

"Partnering with Panoramic Health allows us to bring a higher level of research capability to our patients and our community," stated Dr. Sharma of West Coast Kidney Institute. "This site is designed to deliver both access and performance, connecting patients to innovative therapies while giving sponsors a reliable, high-quality research partner."

The institute's launch not only promises medical breakthroughs but also contributes to the local economy by creating specialized jobs and attracting further investment into the region's robust life sciences sector. It acts as a magnet for talent and a critical piece of infrastructure that enables global health advancements to originate locally.

From Clinical Care to Cutting-Edge Trials

The establishment of the Concord Cardio-Renal Research Institute is a powerful illustration of the evolving healthcare landscape, where the lines between providing care and pioneering it are blurring. For parent company Panoramic Health, this move is a logical extension of its core mission. Founded by nephrologists, the company has built a vast network supporting kidney specialists across the country, focusing on slowing disease progression and improving quality of life.

By creating Panoramic Science and investing in dedicated research sites like the one in Concord, the organization is leveraging its deep clinical roots and patient network to advance the science of nephrology and related fields. This strategy transforms a network of care providers into a powerful engine for discovery. It creates a virtuous cycle where clinical insights from thousands of patient interactions can inform research questions, and in turn, patients within the network gain early access to the very therapies being developed to address their conditions.

This model represents a shift from a system that simply treats disease to one that actively works to defeat it through integrated research. By embedding trial capabilities directly within the patient care journey, the Concord Cardio-Renal Research Institute is poised to not only accelerate the path of new drugs to market but also redefine the role that community-based specialty practices can play in the future of medicine.